Holen Sie sich die Stockscreener-App
0.3381
12.93%
0.0458
Schlusskurs vom Vortag:
$0.2923
Offen:
$0.4201
24-Stunden-Volumen:
40.83M
Relative Volume:
48.14
Marktkapitalisierung:
$2.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.28M
KGV:
-0.0243
EPS:
-13.91
Netto-Cashflow:
$-13.75M
1W Leistung:
-54.79%
1M Leistung:
-54.04%
6M Leistung:
-63.94%
1J Leistung:
-89.35%
1-Tages-Spanne:
$0.32
$0.435
1-Wochen-Bereich:
$0.281
$0.7269
52-Wochen-Spanne:
$0.281
$3.85
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Firmenname
Pasithea Therapeutics Corp
Sektor
Branche
Telefon
(702) 514-4174
Adresse
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Vergleichen Sie KTTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.3369 | 2.18M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.59 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
757.36 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.47 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
906.07 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.73 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten
You might want to take a look at Pasithea Therapeutics Corp (KTTA) now - Setenews
Pasithea Therapeutics announces completion of cohort 7 in ongoing phase 1 trial of PAS-004 - MarketScreener
Pasithea Therapeutics Announces Completion Of Cohort 7 In Ongoing Phase 1 Trial Of Pas-004 - TradingView
Pasithea reports positive safety data from PAS-004 cancer trial - Investing.com
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data - Yahoo Finance
Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 29.6% – Should You Sell? - Defense World
Pasithea Therapeutics says positive PAS-004 tablet pharmacokinetic data in ongoing Phase 1/1b trial in adult NF1 patients - MarketScreener
Pasithea Therapeutics Says Positive PAS-004 Tablet Pharmacokinetic Data In Ongoing Phase 1/1B Trial In Adult NF1 Patients - TradingView
Pasithea Therapeutics' PAS-004 Shows Favorable Pharmacokinetic Properties in Tablets in Phase 1 Trial - MarketScreener
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients - Investing News Network
Pasithea reports positive PK data for PAS-004 tablet formulation By Investing.com - Investing.com India
Pasithea reports positive PK data for PAS-004 tablet formulation - Investing.com
Pasithea Therapeutics Announces Positive PAS-004 Tablet - GlobeNewswire
Pasithea Therapeutics Corp. (KTTA) -23.4% in Normal Trading: Despite Positive Phase 1 Data - Stocks Telegraph
Pasithea reports positive interim data for MEK inhibitor in cancer trial - Investing.com Canada
Real time scanner hits for Pasithea Therapeutics Corp. Equity Warrant explainedMarket Growth Summary & Technical Pattern Based Signals - newser.com
Pasithea Therapeutics announces positive phase 1 data including partial response - MarketScreener
Pasithea Therapeutics stock plunges after Phase 1 interim data release By Investing.com - Investing.com Nigeria
Pasithea Therapeutics stock plunges after Phase 1 interim data release - Investing.com
Pasithea reports positive interim data for MEK inhibitor in cancer trial By Investing.com - Investing.com South Africa
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study - Investing News Network
Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing Cohort - MSN
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Its Stock Has Paid Off Big Time For Pasithea Therapeutics Corp - Setenews
Can Pasithea Therapeutics Corp. Equity Warrant stock resist sector downturns2025 Investor Takeaways & Weekly Consistent Profit Watchlists - newser.com
Why retail investors pile into Pasithea Therapeutics Corp. Equity Warrant stockGap Down & High Conviction Buy Zone Picks - newser.com
Is Pasithea Therapeutics Corp. Equity Warrant stock a buy for dividend growthEarnings Trend Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Why Pasithea Therapeutics Corp. stock is rated strong buy2025 Trade Ideas & Weekly Momentum Picks - newser.com
Does Pasithea Therapeutics Corp. Equity Warrant stock trade at a discount to peers2025 Sector Review & Risk Adjusted Buy and Sell Alerts - newser.com
Can Pasithea Therapeutics Corp. Equity Warrant stock beat market expectations this quarterFed Meeting & Low Drawdown Trading Strategies - newser.com
Is it too late to sell Pasithea Therapeutics Corp.July 2025 Final Week & Reliable Momentum Entry Alerts - newser.com
Pasithea Therapeutics Corp. (KTTA) AI-Powered Stock Analysis - Meyka
Is Pasithea Therapeutics Corp. Equity Warrant stock supported by strong cash flowsRisk Management & Daily Profit Focused Screening - newser.com
Combining price and volume data for Pasithea Therapeutics Corp.Market Risk Report & Daily Stock Momentum Reports - newser.com
Understanding Pasithea Therapeutics Corp. Equity Warrant’s price movementOil Prices & Weekly Watchlist for Consistent Profits - newser.com
Short interest data insights for Pasithea Therapeutics Corp.2025 Price Momentum & Low Risk Entry Point Guides - newser.com
Is Pasithea Therapeutics Corp. stock cheap compared to fundamentalsIndex Update & Stock Portfolio Risk Management - newser.com
Multi factor analysis applied to Pasithea Therapeutics Corp.Trend Reversal & AI Enhanced Execution Alerts - newser.com
Pasithea Therapeutics Corp. stock chart pattern explained2025 Major Catalysts & Verified Momentum Stock Alerts - newser.com
Pasithea Therapeutics Corp. stock trend forecastQuarterly Profit Report & Daily Market Momentum Tracking - newser.com
How currency fluctuations impact Pasithea Therapeutics Corp. Equity Warrant stockJuly 2025 Breakouts & Reliable Trade Execution Plans - newser.com
[S-1] Pasithea Therapeutics Corp. Files IPO Registration Statement | KTTA SEC FilingForm S-1 - Stock Titan
Finanzdaten der Pasithea Therapeutics Corp-Aktie (KTTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pasithea Therapeutics Corp-Aktie (KTTA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
May 12 '25 |
Sale |
0.82 |
960 |
792 |
40,001 |
1.27%
5.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):